Antidiabetics Market Expected to Achieve 11.3% CAGR by 2029: Growth Forecast Insights

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Antidiabetics Market Size By 2025?
The scale of the antidiabetics market has seen a swift expansion in the past few years. The market value will rise from $76.03 billion in 2024 to $84.84 billion in 2025, with a compound annual growth rate (CAGR) of 11.6%. The accelerated growth witnessed in the historical phase is a result of factors such as the increasing number of global diabetes cases, innovation in drug creation, enhanced recognition and diagnosis, encouraging governmental regulations, the rise in the ageing population, a more sedentary way of life, and a boost in healthcare spending.

How Big Is the Antidiabetics Market Size Expected to Grow by 2029?
In the forthcoming years, the size of the antidiabetics market is predicted to expand rapidly, reaching a value of $130.12 billion in 2029 at a compound annual growth rate (CAGR) of 11.3%. This growth within the forecast period can be traced back to factors such as the rising incidence of diabetes, an increase in awareness and diagnosis, growing healthcare spending, an enlarging senior population, and government health initiatives and policies. Key trends for this period include an upswing in GLP-1 receptor agonists and SGLT2 inhibitors, expansion of biologics and biosimilars, emphasis on preventive healthcare, burgeoning market growth, and technology integration.

View the full report here:
https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

Which Key Market Drivers Powering Antidiabetics Market Expansion and Growth?
The prevalence of health problems related to lifestyle choices is predicted to drive the growth of the antidiabetics market. These health issues stem from behaviors like poor dietary habits, inadequate exercise, smoking, and over-consumption of alcohol. Due to deteriorating diet quality, sedentary lifestyles, and heightened stress, the prevalence of these lifestyle-related issues is on the rise. Antidiabetic drugs aid in managing conditions such as obesity and metabolic syndrome by enhancing insulin receptivity and moderating blood glucose levels. For instance, the World Health Organization, an intergovernmental organization based in Switzerland, reported in March 2022 that about 1 billion people globally, comprising 650 million adults, 340 million adolescents, and 39 million children, are obese, a number that is increasing. It's projected that by 2025, approximately 167 million adults and children will face health issues due to obesity or being overweight. Hence, the increasing occurrence of lifestyle-linked conditions is driving the growth of the antidiabetic market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18225&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Antidiabetics Market?
Leading firms in the antidiabetics market are progressing on cutting-edge products such as the anti-diabetic biosimilar. These developments are geared towards enhanced blood sugar control, diminished cardiovascular event potentials, and a wider range of better treatment possibilities for diabetic individuals. An anti-diabetic biosimilar is essentially a medication that is biologically equivalent to an already approved reference medicine used for managing diabetes, providing parallel safety, efficacy, and quality. For instance, in January 2024, the India-based Glenmark Pharmaceuticals Limited introduced the first biosimilar of Liraglutide, a medication for diabetes. The Liraglutide biosimilar, marketed as Lirafit, bolsters blood glucose control in type 2 diabetes mellitus patients. It has been demonstrated in clinical trials that it diminishes glycemic measures, supports weight reduction, and improves cardiovascular safety. Being a GLP-1 receptor agonist, it uplifts glucose-dependent insulin secretion while suppressing improper glucagon secretion. It has been given worldwide approval for the management of type 2 diabetes in adults.

What Are the Emerging Segments in the Antidiabetics Market?
The antidiabetics market covered in this report is segmented -

1) By Drug Class: Insulin, GLP-1 Receptor Agonists, DPP- 4 Inhibitors, SGLT2 Inhibitors, Other Drug Classes,
2) By Diabetes Type: Type 1, Type 2
3) By Patient Population: Antidiabetics For Pediatrics, Antidiabetics For Adults, Antidiabetics For Geriatrics
4) By Route Of Administration: Antidiabetics Administration Through Insulin Syringes Or Insulin Pens, Antidiabetics Administration Through Insulin Pumps, Intravenous Antidiabetics Infusion, Oral Antidiabetics Administration, Other Routes Of Antidiabetics Administration
5) By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Retail Pharmacies

Subsegments:
1) By Insulin: Rapid-Acting Insulin, Short-Acting Insulin, Intermediate-Acting Insulin, Long-Acting Insulin, Premixed Insulin
2) By GLP-1 Receptor Agonists: Exenatide, Liraglutide, Dulaglutide, Semaglutide, Lixisenatide
3) By DPP-4 Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin
4) By SGLT2 Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin
5) By Other Drug Classes: Sulfonylureas, Thiazolidinediones (TZDs), Alpha-Glucosidase Inhibitors, Meglitinides, GLP-1/Insulin Combination Therapy

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=18225&type=smp

Who Are the Global Leaders in the Antidiabetics Market?
Major companies operating in the antidiabetics market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, Takeda Pharmaceutical Company Limited, GSK plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen, Vertex Pharmaceuticals Incorporated, Servier Laboratories, Sun Pharmaceutical Industries Limited, Cipla Limited, Dr. Reddy's Laboratories, Lupin Limited, Torrent Pharmaceuticals Ltd, Biocon Limited, Glenmark Pharmaceuticals Ltd.

Which are the Top Profitable Regional Markets for the Antidiabetics Industry?
North America was the largest region in the antidiabetics market in 2023. The regions covered in the antidiabetics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18225

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.